Join Svar’s webinar and gain unique insights into potency strategies
Bring your potency testing to the next level by connecting assay design to mechanism of action, product quality and clinical relevance. Join Svar Life Science’s latest webinar: Potency Assays for Modern Biologics: Expert Insights and Future Trends – an insightful session exploring potency strategies for modern therapeutics and complex modalities.
Learn how potency assay strategies play an instrumental role across all development stages of biologics by providing biologically meaningful measures of a product’s biological function and quality.
Wednesday, November 11, 2026
9:30am EST / 2:30pm GMT / 3:30pm CET
As the biologics landscape becomes increasingly complex and therapeutic modalities grow more sophisticated, potency assay strategies are evolving from regulatory requirements into powerful tools that provide biologically meaningful measures of product function, quality and mechanism of action.
Join this webinar exploring how developers can design potency testing strategies that generate biologically relevant insights into therapeutic candidates while meeting regulatory expectations.
Industry experts will explore how to develop successful potency strategies for biologics and increasingly complex therapeutic modalities and discuss key decisions and pitfalls, lessons learned, best practices and practical strategies for developing potency assays that are scientifically relevant, fit-for-purpose and phase-appropriate.
Speakers:
- Paulo Roky Bamert, Associate Director, Analytical Development Bioanalytics, Novartis Pharma AG
- Silvia Mattick, People & Science Lead, Senior Scientist, Roche
- Agnieszka Lewandowska, Associate Director, Analytical Development CMC, Immunocore
- Therese Segerstein (Moderator), Portfolio Director, Svar Life Science.
Potency testing sits at the intersection of product characterization, quality control and regulatory compliance, making it one of the most critical and challenging aspects of biologics development. Potency is considered a critical quality attribute (CQA) that links a therapeutic product's mechanism of action (MoA) to its clinical effect and supports biological understanding throughout the development continuum.
As novel therapeutic modalities continue to emerge, developers require function-reflective assays that provide reliable and quantitative measures of biological activity. The speakers will also examine how innovations such as platform technologies, engineered reporter cell systems, assay-ready formats, automation and improved product characterization are shaping the next generation of potency strategies.
Register for this webinar to learn how robust potency testing can support meaningful measures of biological activity, product quality and regulatory readiness across biologics development.
